These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27102929)

  • 1. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
    Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
    Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R
    Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
    Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
    Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
    Mueller BU; Bennett CM; Feldman HA; Bussel JB; Abshire TC; Moore TB; Sawaf H; Loh ML; Rogers ZR; Glader BE; McCarthy MC; Mahoney DH; Olson TA; Feig SA; Lorenzana AN; Mentzer WC; Buchanan GR; Neufeld EJ; ;
    Pediatr Blood Cancer; 2009 Feb; 52(2):259-62. PubMed ID: 18937333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
    Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
    Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C
    Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
    Parodi E; Rivetti E; Amendola G; Bisogno G; Calabrese R; Farruggia P; Giordano P; Matarese SM; Nardi M; Nobili B; Notarangelo LD; Russo G; Vimercati C; Zecca M; De Mattia D; Ramenghi U
    Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
    Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
    Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
    Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
    Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
    Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.